Company Profile
Outlook Stock Price, News & Catalysts
- Ticker:
- OTLK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.68 USD (+0.61%)
Close
Last updated: September 17, 2026
121M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, OTLK closed up 0.61% at $0.6810. No new same-company headline was identified in the current news window.
Company overview
Ophthalmic Bevacizumab Company
Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for oncology use.
LYTENAVA for Wet AMD
LYTENAVA, or bevacizumab-vikg in the United States and bevacizumab gamma in Europe, is a VEGF inhibitor approved for neovascular age-related macular degeneration. By binding VEGF-A, it is intended to suppress abnormal blood-vessel growth and vascular leakage that contribute to progressive vision loss.
US Commercial Franchise
LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD. Outlook is establishing US market access, reimbursement, supply, medical-affairs, patient-support, and retina-specialist commercial capabilities ahead of product availability.
International Commercialization
LYTENAVA is also authorized in the European Union and United Kingdom and has been launched in Germany, Austria, and the UK. Outlook is pursuing additional country launches directly and through regional distribution partners.
Future catalysts
- Commercial launch of LYTENAVA in the United States before the end of 2026.
- Commercial launch of LYTENAVA in the Netherlands later in 2026.
- Potential Swiss approval and partner-led commercial launch of LYTENAVA in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Outlook (OTLK)?
Outlook (OTLK) most recently closed at 0.68 USD, a +0.61% move versus the previous session.
What is the market cap of Outlook (OTLK)?
Outlook currently has a market capitalization of 121M USD on BioPharmSignal.
What does Outlook do?
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for oncology use. LYTENAVA...
On which exchange is OTLK stock listed?
Outlook (OTLK) is associated with NASDAQ, United States, Biopharma.
What is VEGF-A?
By binding VEGF-A, it is intended to suppress abnormal blood-vessel growth and vascular leakage that contribute to progressive vision loss.
Which conditions is Outlook targeting with VEGF-A?
Outlook is associated with oncology, ophthalmology based on its company overview and current catalyst commentary.
How does Outlook describe recent progress with VEGF-A?
Commercial launch of LYTENAVA in the United States before the end of 2026. Commercial launch of LYTENAVA in the Netherlands later in 2026. Potential Swiss approval and partner-led commercial launch of LYTENAVA in 2027.
What is bevacizumab?
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases.